Objectives. We aimed to identify whether presentations and outcomes in adult patients with isolated small-vessel primary angiitis of the CNS (PACNS) would differ from other patients with large/mediumvessel involvement.
Introduction
Adult primary angiitis of the CNS (PACNS) is a rare inflammatory condition affecting CNS vessels. Diagnosis relies on the presence of isolated neurological symptoms along with evidence of brain vessel involvement and the exclusion of all mimicking conditions or secondary causes of CNS vasculitis [13] . Biopsy remains the gold-standard procedure to highlight the vasculitis process but is performed in less than half of patients in practice and can reveal some negative results [4, 5] . In patients with noncontributive biopsy or without biopsy, diagnosis relies on demonstration of vascular involvement on neurovascular imaging, such as digital subtraction angiography (DSA), magnetic resonance angiography (MRA) or cerebral angio-CT scan.
The few published cohorts of adult PACNS suggested the existence of different disease patterns [4, 611] . Separating disease subgroups according to the size of the affected vessels is straightforward. In children, patients with angiography-negative PACNS were more likely to present with seizures, cognitive dysfunction, abnormalities of vision, high levels of inflammatory markers and bilateral findings on MRI [1113] . In adults, results from the North American cohort suggested more cognitive disorders, abnormal cerebrospinal fluid (CSF) analysis and gadolinium-enhanced lesions in the eight patients with small-vessel angiography-negative PACNS, when compared with 76 angiography-positive patients [14] . Whether the presentation and outcomes of isolated small-vessel PACNS differ from those of patients with large/medium-vessel involvement requires confirmation in separate and/or larger cohorts.
Therefore, we re-analysed patients from the French PACNS cohort and compared those who had isolated small-vessel PACNS with those who had large/mediumvessel involvement.
Methods

Patients
Patients were enrolled from the French cohort initiated in 2010 using the well-established networks of the French Vasculitis Study Group, French NeuroVascular Society and National Society of Internal Medicine. All patients were aged >18 years and underwent a complete workup at diagnosis (whole body imaging, echocardiography and complete immunological and infection screening, including ANAs, ANCA and tests to rule out HIV, HBV and HBC, syphilis, tuberculosis and CMV) to exclude other conditions affecting CNS vessels (e.g. systemic vasculitis, CTD, infection, malignancies). Patients with presentation and/or outcomes compatible with vasculopathy, such as atherosclerosis or reversible vasoconstriction syndrome, were excluded. Reversible vasoconstriction syndrome was excluded in our patients on the clinical presentation (no thunderclap headaches, no recent use of vasoconstrictive drugs, not post-partum) and the persistence of vascular lesions on repeat neuroimaging >3 months after disease onset.
In June 2016, the cohort included 109 patients. A description of the first 52 enrolled patients was published in 2014 [4] . All patients had evidence of vessel involvement on biopsy (n = 34), DSA (n = 65) or MRA (n = 10). Seven patients with a follow-up <3 months were not included; all the 102 others had been followed up for at least 6 months (or had died earlier of a biopsy-proven PACNS).
This cohort has been supported by an institutional grant from the French Ministry of Health (COVAC, 2009 PHRC 08017). Inclusion in the cohort required patient informed consent, and the cohort was approved by the ParisCochin Institutional Review Board (no. 12541). This study did not require additional approval. The manuscript was prepared in accordance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) principles [15] .
Studied variables and definitions
Using a standardized form, the characteristics of each patient were retrieved from their medical records, as described earlier [4] . Results of MRI were collected. Acute ischaemic lesions corresponded to high intensities on diffusion-weighted imaging with restricted diffusion on apparent diffusion coefficient mapping; haemorrhages appeared as a hypointense signal on T2*-weighted sequences. CSF analysis findings were considered abnormal with a leucocyte count >5 cells/ml and/or a total protein level >0.5 mg/ml.
In neurovascular imaging, PACNS typically presented with multiple smooth-wall segmental narrowing, dilatations and/or occlusions. We differentiated between large/medium-sized vessel PACNS and small-vessel PACNS. Intracranial internal carotid and proximal and second divisions of cerebral arteries were considered large/medium-sized vessels and were seen on neurovascular imaging, whereas subsequent branches were considered small sized and assessable only on biopsy. Patients with isolated small-vessel PACNS thus had negative neurovascular imaging studies and positive biopsies.
Functional neurological status was evaluated using the modified Rankin scale (mRs; calculated retrospectively based on medical records for patients enrolled retrospectively): 0 = no neurological deficits; 1 = no significant disability, despite symptoms; 2 = slight disability; 3 = moderate disability; 4 = moderately severe disability; 5 = severe disability; and 6 = death [16] . The mRs was calculated before starting treatment and at the last follow-up. A good functional and neurological outcome was defined as preserved autonomy and mRs 42 at last follow-up, regardless of the occurrence of relapse(s) during the disease course. Poor outcomes were defined as mRs >2 at last follow-up and/or death. Relapse was defined as the re-occurrence of neurological symptoms and/or neuroimaging worsening, leading to treatment adjustment and intensification. 
Results
We identified 26 (25%) patients with isolated small-vessel PACNS, who were compared with 76 patients with large/ medium-vessel involvement. Characteristics of the cohort and of each group are shown in Table 1 . All patients with isolated small-vessel PACNS had negative neurovascular imaging. Seven of them did not undergo DSA, but an MRA (on a 1.5 and a 3 T unit in four and three, respectively) was performed, which was negative.
Presentation of patients who had isolated small-vessel PACNS compared with other patients who had large/medium-vessel involvement
Patients who had isolated small-vessel PACNS were younger than other patients (P = 0.04). They had more seizures (P < 0.0001), cognitive impairment (P = 0.02), impaired level of consciousness (P = 0.03) and dyskinesias (P = 0.002) but less focal deficits (P = 0.0002). They also had more abnormal CSF analysis (P = 0.008). MRI patterns were different in both groups, as patients who had isolated small-vessel PACNS showed more gadolinium enhancements (leptomeningeal and parenchymal, P = 0.0005 and P = 0.0005, respectively; Fig. 1A and B) and tumour-like lesions (P < 0.0001), whereas acute ischaemic lesions were more frequent in patients with demonstration of large/medium-vessel involvement (P < 0.0001; Fig. 1C and D) .
Treatment and outcomes
Induction treatment consisted of glucocorticoids (GCs) in all but two patients, along with an immunosuppressant in 86 (84%), including the two patients who did not receive GC. CYC was administered to 84 patients, with i.v. infusions in 81, whereas the three others received daily oral CYC. Rituximab was used in induction in the two remaining patients. Aspirin was concomitantly prescribed in 39 (38%) patients, all of whom presented large/mediumvessel involvement (P < 0.0001). After induction, 48 (47%) patients received maintenance therapy (AZA, MTX and MMF in 38, 6 and 4 cases, respectively). Dosage, use of i.v. pulses of methylprednisolone and duration of GCs, use of CYC and maintenance therapy did not differ in patients according to the size of predominantly affected vessels or the histological pattern of PACNS. With a total follow-up duration of 52.5 (0198) months, 58 (57%) had good functional outcomes, with no difference between these latter subgroups (P = 0.41). At the last follow-up, 78 (76%) patients had discontinued their treatments and the median mRs was 2 (06).
Eight (8%) patients died; two (8%) with isolated smallvessel PACNS vs six (8%) with demonstration of large/ medium-vessel involvement (P = 0.97). Four of them with biopsy-proven PACNS died within a few weeks of disease onset and four during a relapse, 15 (537) months after GC onset.
Relapse was observed in 32 (31%) patients, 16 (5145) months after diagnosis, mainly in patients with isolated small-vessel PACNS [14 (54%) with isolated small-vessel PACNS vs 18 (24%) with demonstration of large/mediumvessel involvement; P = 0.004].
Relapse rate or functional outcomes did not differ according to the histological pattern in patients with a biopsy-proven diagnosis.
Discussion
Diagnosis of PACNS is challenging, and our study is a reminder of how polymorphic and non-specific the initial presentation can be. Identification of disease subgroups from the three main cohorts [4, 10, 11] improves our knowledge and supports the following two paradigms: (i) patients with isolated small-vessel PACNS have a more severe encephalopathic presentation (i.e. cognitive or vigilance impairment, seizures), more abnormal CSF analysis and more diffuse gadolinium-enhanced lesions on MRI [1214] . Conversely, patients with large/medium-vessel demonstration show more focal vascular involvement, responsible for stroke presentation with focal deficits. In these patients, acute ischaemia is frequent on MRI, and neurovascular imaging contributes to highlighting large/ medium vascular involvement [5, 12] ; and (ii) patients with isolated small-vessel PACNS are more prone to relapse [12] .
Interestingly, while we found some relevant differences at onset in both groups, we did not find any differences in functional outcomes at the last follow-up. Apart from more relapses in patients with isolated small-vessel PACNS, we found a similar rate of good outcomes and treatment discontinuation in both groups. This contradicts the results obtained by Salvarani et al. [5] , who showed poorer outcomes in patients with large-vessel involvement and lower disability in patients with gadolinium-enhanced lesions. Our longer follow-up (>4 vs 1 year) may explain the different long-term outcomes as well as the different treatment regimens in both cohorts. Moreover, differences in histological patterns in both cohorts may explain some different outcomes. While lymphocytic pattern was the most frequent pattern observed on biopsy in France, involving 84% of patients, a granulomatous inflammatory pattern was the most frequent observation in the Mayo Clinic's cohort, involving 59% of patients [10] . Interestingly, Salvarani et al.
[10] observed a trend toward a reduction in the percentage of patients with poor outcomes at the last follow-up in the lymphocytic pattern group. This difference in histological patterns could explain, at least in part, the lower mortality in our cohort compared with that presented by Salvarani et al. [10] . Large-vessel involvement was also associated with an increased mortality rate in the North American cohort, whereas gadolinium enhancements were protective [5]. We did not observe such a difference, but our mortality rate was almost twice as low (8 vs 15%), which limits the number of patients and the ability to compare them in both groups.
Treatment of PACNS is not standardized, and some relevant differences exist among the different cohorts [17, 18] . Our patients received longer GC treatments (24 vs 9 months), more immunosuppressants (>80% of our patients received CYC vs 44% in the North American cohort) and more maintenance therapy (47 vs 24%) than patients in the cohort of Salvarani et al.
[5], which may explain the lack of differences regarding outcomes in both our groups. Patients with isolated small-vessel PACNS showed good outcomes in the North American cohort with GC treatment alone [5] . However, in the present study, relapses were more frequent in patients treated with GC alone. Finally, although these findings deserve confirmation in prospective studies, our results indicate that a combination of GC and an immunosuppressant is probably required at treatment induction.
Besides the strengths of our study, which are the long follow-up and the high number of patients cured of PACNS (>75% did not have treatment at last follow-up), the retrospective design limits the exhaustiveness of retrieved data. However, updated information was obtained in each patient by contacting the treating physician. The low rate of biopsy-proven PACNS could be considered as another drawback. However, this rate does not differ from that of another large adult cohort from the Mayo clinic (36%) [5] and emphasizes the fact that, despite being recognized as carrying the best diagnostic value, brain biopsy is not systematically performed in routine practice and is not as sensitive as often believed [19] . Our patients underwent an extensive work-up to exclude other diseases affecting CNS vessels, although a few can be really challenging, mimic PACNS and respond initially to the same medications, especially intravascular CNS lymphoma.
In conclusion, our study suggests that patients with PACNS differ depending on the size of predominantly affected brain vessels. Patients with isolated small-vessel disease have a more severe encephalopathic presentation, whereas those with larger vessel disease have more strokes at presentation. Although more relapses were observed in patients with isolated small-vessel PACNS, long-term functional outcomes or mortality did not differ between groups when treated with a combination of GC and an immunosuppressant. Prospective international studies are required to confirm these findings.
